Literature DB >> 22932320

Programmatic impact of the evolution of WHO pediatric antiretroviral treatment guidelines for resource-limited countries (Tukula Fenna Project, Uganda).

Martina Penazzato1, Siobhan Crowley, Lynne Mofenson, Genny Franceschetto, Maria-Musoke Nannyonga, Antonio Mazza, Carlo Giaquinto.   

Abstract

BACKGROUND: World Health Organization (WHO) recommendations for the initiation of antiretroviral therapy (ART) in children were revised in 2010, but the programmatic impact has had limited study.
METHODS: We used a cohort of 985 Ugandan children followed since 2003 by the Tukula Fenna project to model the differential impact of the 2006, 2008, and 2010 WHO pediatric ART inititation criteria on the proportion of children eligible for ART at enrollment and over time.
RESULTS: Using the WHO 2006, 2008, and 2010 ART criteria, 40%, 57%, and 66% of children, respectively, would have been eligible for ART at enrollment and 76%, 84%, and 88% 2 years later. Evaluating the entire cohort followed for 6 years using the 2006, 2008, and 2010 guidelines, the proportion in need of ART was found to be 70%, 82%, and 87%, respectively. Between 2006 and 2008, the proportions of eligible children starting ART within 6 and 12 months were 39% and 50%, respectively; after this, the proportions starting within 6 and 12 months were 50% and 52%. Before 2008, the most common criterion met in children who did not start ART was WHO clinical stage (odds ratio = 2.0, CI 95% = 1.2 to 3.2); after the 2008 recommendations, the most common eligibility criterion in children who did not start ART was age <12 months (odds ratio = 10.5, CI 95% = 3.8 to 31.1).
CONCLUSIONS: An overall increase of 17% (from 70% to 87%) in children in need of ART was observed in our cohort comparing the 2006 and 2010 guidelines; this increase was primarily driven by the introduction of universal treatment for infants <12 months in 2008.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22932320     DOI: 10.1097/QAI.0b013e31826f369d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Rapid Diagnostic Testing of Hospitalized Malawian Children Reveals Opportunities for Improved HIV Diagnosis and Treatment.

Authors:  Theresa F Madaline; Sarah E Hochman; Karl B Seydel; Alice Liomba; Alex Saidi; Grace Matebule; Wenzhu B Mowrey; Bernadette O'Hare; Danny A Milner; Kami Kim
Journal:  Am J Trop Med Hyg       Date:  2017-10-12       Impact factor: 2.345

2.  Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Authors:  Philippe R Mutwa; Kimberly R Boer; Brenda Asiimwe-Kateera; Diane Tuyishimire; Narcisse Muganga; Joep M A Lange; Janneke van de Wijgert; Anita Asiimwe; Peter Reiss; Sibyl P M Geelen
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

3.  Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration.

Authors:  Azar Kariminia; Matthew Law; Mary-Ann Davies; Michael Vinikoor; Kara Wools-Kaloustian; Valeriane Leroy; Andrew Edmonds; Catherine McGowan; Rachel Vreeman; Lee Fairlie; Samuel Ayaya; Marcel Yotebieng; Elom Takassi; Jorge Pinto; Adebola Adedimeji; Karen Malateste; Daisy M Machado; Martina Penazzato; Rohan Hazra; Annette H Sohn
Journal:  J Int AIDS Soc       Date:  2018-12       Impact factor: 5.396

4.  Factors Determining Survival and Retention among HIV-Infected Children and Adolescents in a Community Home-Based Care and a Facility-Based Family-Centred Approach in Kampala, Uganda: A Cohort Study.

Authors:  W Massavon; L Barlow-Mosha; L Mugenyi; W McFarland; G Gray; R Lundin; P Costenaro; M M Nannyonga; M Penazzato; D Bagenda; C P Namisi; D Wabwire; M Mubiru; S Kironde; D Bilardi; A Mazza; M G Fowler; P Musoke; C Giaquinto
Journal:  ISRN AIDS       Date:  2014-04-01

5.  Using Observational Data to Inform HIV Policy Change for Children and Youth.

Authors:  Annette H Sohn; Ali Judd; Lynne Mofenson; Marisa Vicari; Degu Jerene; Valeriane Leroy; Linda-Gail Bekker; Mary-Ann Davies
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.